Patents by Inventor Anantha Sudhakar

Anantha Sudhakar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220024938
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Patent number: 11174262
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: November 16, 2021
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Publication number: 20210087176
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: November 27, 2020
    Publication date: March 25, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20210009566
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Application
    Filed: December 19, 2018
    Publication date: January 14, 2021
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Patent number: 10851088
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 1, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Patent number: 10709692
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 14, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • Publication number: 20200079784
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Publication number: 20190315723
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 17, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Patent number: 10370361
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 6, 2019
    Assignee: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20190194170
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 27, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20190084978
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: April 11, 2018
    Publication date: March 21, 2019
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Publication number: 20180353480
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • Patent number: 9969730
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Patent number: 9839630
    Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: December 12, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Tamilarasan Subramani, Mohamed Rahuman, Ramar Subbiah
  • Publication number: 20170226104
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Patent number: 9676774
    Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: June 13, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Marc J. Evanchik, Anantha Sudhakar, Jeffrey William Jacobs, Jeffrey A. Silverman
  • Publication number: 20170101404
    Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.
    Type: Application
    Filed: May 16, 2016
    Publication date: April 13, 2017
    Inventors: Daniel C. Adelman, Marc J. Evanchik, Anantha Sudhakar, Jeffrey William Jacobs, Jeffrey A. Silverman
  • Publication number: 20170035741
    Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.
    Type: Application
    Filed: March 8, 2016
    Publication date: February 9, 2017
    Inventors: Anantha SUDHAKAR, Tamilarasan SUBRAMANI, Mohamed Sheik Mohamed Mujeebur RAHUMAN, Ramar SUBBIAH
  • Patent number: 9469635
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: October 18, 2016
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Publication number: 20150157614
    Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.
    Type: Application
    Filed: July 11, 2014
    Publication date: June 11, 2015
    Inventors: Anantha Sudhakar, Tamilarasan Subramani, Mohamed Sheik Mohamed Mujeebur Rahuman, Ramar Subbiah